Login:
 
Lockyer M. SGLT2 inhibitor produces good glycaemic control in everyday practice. Practitioner April 2019;263(1825):8-9

SGLT2 inhibitor produces good glycaemic control in everyday practice

24 Apr 2019Registered users

An observational study from Scotland has shown that dapagliflozin produced equivalent improvements in glycaemic control in patients with type 2 diabetes in general practice to those reported in clinical trials.

Registered usersThis article can only be accessed if you are a registered user of thepractitioner.co.uk or a subscriber to The Practitioner.

To buy this article (£25+tax) copy the article citation above and click Buy article